Renalytix PLC
LSE:RENX
Renalytix PLC
LSE:RENX
Price:
23.5 GBX
-4.08%
Market Closed
Updated:
May 16, 2024
P/S
Price to Sales
Price to Sales
13.5
Current
51.9
Median
2.4
Industry
Lower
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=13.5
Market Cap
/
36.3m
Revenue
3.4m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| UK |
|
Renalytix PLC
LSE:RENX
|
36.3m GBP | 13.5 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
33.7B USD | 14.3 | |
| US |
|
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 4.8 | |
| US |
|
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 2.6 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
12.5B AUD | 85.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY | 4.7 | |
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
4.7B USD | 7.1 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.4B USD | 9.4 | |
| SE |
|
Sectra AB
STO:SECT B
|
45.4B SEK | 27.7 | |
| US |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
3B USD | 4 | |
| US |
|
Vocera Communications Inc
NYSE:VCRA
|
2.8B USD | 11.7 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
0.1
2-Years Forward
P/S
0
3-Years Forward
P/S
0
You don't have any saved screeners yet
